Australia’s Cochlear hits decade low after slashing profit guidance

Cochlear cut FY26 underlying net profit guidance sharply to A$290 million-A$330 million from A$435 million-A$460 million, and the stock fell 38.2% to A$103.87, a 10-year low. Second-half sales growth is now expected at just 2%–6% in constant currency, with weak demand in developed markets, especially adults and seniors, plus hospital constraints and softer U.S. consumer sentiment. The company also flagged Middle East conflict risks, including possible order cancellations, delivery delays, a potential A$10 million receivables hit, and about A$25 million of after-tax FX pressure.

Analysis

This is less a one-off miss than an exposure to a slowing replacement cycle. Implant demand is highly dependent on elective pathway throughput: when hospitals are capacity-constrained and referral conversion weakens, revenue can gap down faster than management can flex costs, so near-term margin compression is likely to be more persistent than the market expects. The size of the guidance reset also suggests the business is more operationally levered than the stock’s prior defensive healthcare multiple implied.

Second-order, the pressure is not just on the company but on the ecosystem around it. Audiology clinics, surgical centers, and distributor inventories likely see delayed purchases and lower attach rates, which can create a temporary air pocket for peer sales even after the initial miss is digested. If developed-market consumer sentiment stays soft, this can morph from a one-quarter demand issue into a multi-quarter share loss problem as hospitals prioritize higher-throughput procedures over niche implants.

The geopolitical overlay matters because it is additive, not substitutive. FX weakness and receivable risk both hit P&L, but the bigger issue is behavioral: any perception of delivery uncertainty in the Middle East can cause customers to defer orders preemptively, extending the revenue trough beyond the actual conflict window. The contrarian take is that the equity may still not fully discount a second leg lower if consensus is assuming a clean H2 recovery; we think the risk/reward is skewed to another cut before stabilization.

Key Decisions for Investors

• Short COH on any relief bounce over the next 1-3 sessions; risk/reward favors fading rallies until management proves referral volumes are stabilizing
• Pair trade: long defensives with less elective exposure vs short COH in the healthcare sleeve for the next 1-2 quarters; the key edge is lower operating leverage and less dependence on hospital throughput
• Buy COH put spreads with 2-4 month tenor to express a downside continuation view while capping theta bleed; target another guidance reset or margin compression update as the catalyst
• If forced to own the name, wait for evidence of developed-market volumes and FX stabilization before adding; absent that, upside is likely limited to short-covering rather than fundamental re-rating